# Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

> **NCT03270007** · PHASE4 · UNKNOWN · sponsor: **Tao OUYANG** · enrollment: 304 (estimated)

## Conditions studied

- Primary Breast Cancer

## Interventions

- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT03270007
- **Lead sponsor:** Tao OUYANG
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-10
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03270007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03270007, "Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03270007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*